Biological markers and schizophrenia

References

• Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611–1616
   PubMed Web of Science ®Google Scholar
• Kendell RE. The choice of diagnostic criteria for biological research. Archives of General Psychiatry 1982; 39: 1334–1339
   PubMed Web of Science ®Google Scholar
• Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry 1998; 172: 110–120
   PubMed Web of Science ®Google Scholar
• Raz S, Raz N. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. Psychology Bulletin 1990; 108: 93–108
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Swayze VW, Flaum M, Yates WR, Arndt S, McChesney C. Ventricular enlargement in schizophrenia evaluated with computer tomographic scanning. Effects of gender, age, and stage of illness. Archives of General Psychiatry 1990; 47: 1008–1015
   PubMed Web of Science ®Google Scholar
• Roy PD, Zipursky RB, Saint‐Cyr JA, Bury A, Langevin R, Seeman MV. Temporal horn enlargement is present in schizophrenia and bipolar disorder. Biological Psychiatry 1998; 44: 418–422
   PubMed Web of Science ®Google Scholar
• Jones PB, Harvey I, Lewis SW, et al. Cerebral ventricle dimensions as risk factors for schizophrenia and affective psychosis: an epidemiological approach to analysis. Psychological Medicine 1994; 24: 995–1011
   PubMed Web of Science ®Google Scholar
• Harvey I, McGuffin P, Williams M, Toone BK. The Ventricle‐brain ratio (vbr) in functional psychoses. An admixture analysis. Psychiatry Research: Neuroimaging 1989; 35: 61–69
   Web of Science ®Google Scholar
• Daniel DG, Goldberg TE, Gibbons RD, Weinberger DR. Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls. Biological Psychiatry 1991; 30: 887–903
   PubMed Web of Science ®Google Scholar
• Suddath RL, George MD, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. New England Journal of Medicine 1990; 322: 789–794
   PubMed Web of Science ®Google Scholar
• Sharma T, Lancaster E, Lee D, et al. Brain changes in schizophrenia. Volumetric MRI study of families multiply affected with schizophrenia – The Maudsley Family Study 5. British Journal of Psychiatry 1998; 173: 132–138
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 1999; 46: 729–739
   PubMed Web of Science ®Google Scholar
• Knoll IV, Garver DL, Ramber JE, Kingsbury SJ, Croissant D, McDermott B. Heterogeneity of the psychoses: is there a neurodegenerative psychosis?. Schizophrenia Bulletin 1998; 24: 365–379
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Alvir JM, Koreen PHA, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14: S13–S21
   PubMed Web of Science ®Google Scholar
• Laruelle M. Imaging dopamine transmission in schizophrenia. Quarterly Journal of Nuclear Medicine 1998; 42: 211–221
   PubMedGoogle Scholar
• Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug‐naïve schizophrenia. Science 1986; 234: 1558–1563
   PubMed Web of Science ®Google Scholar
• Crawley JC, Owens DG, Crow TJ, et al. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 1986; 2: 224–225
   PubMed Web of Science ®Google Scholar
• Farde L, Wiesel FA, Stone‐Elander S, et al. D2 dopamine receptors in neuroleptic‐naïve schizophrenic patients. Archives of General Psychiatry 1990; 47: 213–219
   PubMed Web of Science ®Google Scholar
• Nordstram AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2 and 5‐HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry 1995; 152: 1444–1449
   PubMed Web of Science ®Google Scholar
• Nyburg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia. International Clinical Psychopharmacology 1998; 13: S15–S20
   Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5‐HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 1999; 156: 286–293
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi‐Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine‐induced dopamine release in drug‐free schizophrenic subjects. Proceedings of the National Academy of Science USA 1996; 99: 9235–9240
   Web of Science ®Google Scholar
• Abi‐Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry 1998; 155: 761–767
   PubMed Web of Science ®Google Scholar
• Tuckwell HC, Koziol JA. A meta‐analysis of homovanillic acid concentrations in schizophrenia. International Journal of Neuroscience 1993; 73: 109–114
   PubMed Web of Science ®Google Scholar
• Copolov DL, Keks NA, Kulkarni J, et al. Prolactin response to low‐dose halperidol challenge in schizophrenic, non‐schizophrenic psychotic, and control subjects. Psychoneuroendocrinology 1990; 15: 225–231
   PubMed Web of Science ®Google Scholar
• Keks NA, McKenzie DP, Low LH, et al. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients. Biological Psychiatry 1992; 32: 426–437
   PubMed Web of Science ®Google Scholar
• Wieselgren IM, Lindstrom LH. CSF levels of HVA and 5‐HIAA in drug free schizophrenic patients and healthy controls: a prospective study focussed on their predictive value for outcome in schizophrenia. Psychiatry Research 1998; 81: 101–110
   PubMed Web of Science ®Google Scholar
• Bowers MB. Lumber CSG 5‐hydroxyindoleacetic acid and homovanillic acid in affective syndromes. Journal of Nervous and Mental Disease 1974; 158: 325–330
   PubMed Web of Science ®Google Scholar
• Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and health controls. British Journal of Psychiatry 1985; 147: 276–282
   PubMed Web of Science ®Google Scholar
• Lindstrom LH. Low HVA and normal 5‐HIAA CSF levels in drug‐free schizophrenic patients compared to health volunteers: correlations to symptomatology and family history. Psychiatry Research 1985; 14: 265–273
   PubMed Web of Science ®Google Scholar
• Maas JW, Bowden CL, Miller AL, et al. Schizophrenia, psychosis and cerebral spinal fluid homovanillic acid concentrations. Schizophrenia Bulletin 1997; 23: 147–154
   PubMed Web of Science ®Google Scholar
• Gomes UCR, Shanley BC, Potgieter L, Roux JT. Noradrenergic overactivity in chronic schizophrenia: evidence based cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. British Journal of Psychiatry 1980; 137: 346–351
   PubMed Web of Science ®Google Scholar
• Gerner RH, Fairbanks L, Anderson GM, et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. American Journal of Psychiatry 1984; 141: 1533–1540
   PubMed Web of Science ®Google Scholar
• Pickar D, Breier A, Hsiao JK, et al. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychoses. Archives of General Psychiatry 1990; 47: 641–648
   PubMed Web of Science ®Google Scholar
• Kirch DG, Suddath RL, Gerhardt GA, Issa F, Freedman R, Wyatt RL. Analysis of cerebrospinal fluid monoamines in schizophrenic patients on and off neuroleptic treatment and compared with health controls. Schizophrenia Research 1991; 4: 349
   Web of Science ®Google Scholar
• Maas JW, Contreras SA, Miller AL, et al. Studies of catecholamine metabolism in schizophrenia/psychosis‐I. Neuropsychopharmacology 1993; 8: 97–109
   PubMed Web of Science ®Google Scholar
• Davidson M, David KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Archives of General Psychiatry 1988; 45: 561–563
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Iwamoto N, Arai H. First‐episode neuroleptic‐free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biological Psychiatry 1997; 41: 857–864
   PubMed Web of Science ®Google Scholar
• Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophrenia Bulletin 1992; 18: 123–148
   PubMed Web of Science ®Google Scholar
• Hutton S, Kennard C. Oculomotor abnormalities in schizophrenia: a critical review. Neurology 1998; 50: 604–609
   PubMed Web of Science ®Google Scholar
• Thaker GK, Kirkpatrick B, Buchanan RW, Ellsberry R, Lahti A, Tamminga C. Oculomotor abnormalities and their clinical correlates in schizophrenia. Psychopharmacology Bulletin 1989; 25: 491–497
   PubMedGoogle Scholar
• King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica 1994; 380: 53–58
   Web of Science ®Google Scholar
• Holzman PS, Proctor LR, Levy DL, Yasillo NJ, Meltzer HY, Hurt SW. Eye‐tracking dysfunctions in schizophrenic patients and their relatives. Archives of General Psychiatry 1974; 31: 143–151
   PubMed Web of Science ®Google Scholar
• Lencer R, Malchow CP, Trillenberg‐Krecker K, Schwinger E, Arolt V. Eye‐tracking dysfunction (ETD) in families with sporadic and familial schizophrenia. Biological Psychiatry 2000; 47: 391–401
   PubMed Web of Science ®Google Scholar
• Arolt V, Lencer R, Nolte A, et al. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosone 6p in families with multiple occurrence of the disease. American Journal of Medicine Genetics 1996; 67: 564–579
   PubMed Web of Science ®Google Scholar
• Freedman R, Adler LE, Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biological Psychiatry 1999; 45: 551–558
   PubMed Web of Science ®Google Scholar
• Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genetics 1995; 11: 201–203
   PubMed Web of Science ®Google Scholar